Compare MNMD & TMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNMD | TMP |
|---|---|---|
| Founded | 2019 | 1836 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | MNMD | TMP |
|---|---|---|
| Price | $14.93 | $74.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | $30.33 | ★ $74.00 |
| AVG Volume (30 Days) | ★ 2.3M | 59.3K |
| Earning Date | 03-05-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 3.54% |
| EPS Growth | N/A | ★ 27.02 |
| EPS | N/A | ★ 5.90 |
| Revenue | N/A | ★ $316,920,000.00 |
| Revenue This Year | N/A | $16.28 |
| Revenue Next Year | N/A | $1.90 |
| P/E Ratio | ★ N/A | $12.45 |
| Revenue Growth | N/A | ★ 10.67 |
| 52 Week Low | $4.70 | $54.16 |
| 52 Week High | $15.29 | $77.33 |
| Indicator | MNMD | TMP |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 57.43 |
| Support Level | $12.88 | $72.80 |
| Resistance Level | $15.20 | $75.34 |
| Average True Range (ATR) | 0.92 | 1.72 |
| MACD | 0.11 | -0.20 |
| Stochastic Oscillator | 85.91 | 78.37 |
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.